MBrace Therapeutics

We’re excited to announce that?MBrace was shortlisted for Best New Drug Developer and Most Promising Clinical Candidate (MBRC-101) at the 11th Annual World ADC Awards! ? Thank you, World ADC Event Series, for this honor. This recognition highlights the dedication and expertise of our purpose-built team working tirelessly to advance innovative #ADC therapies in oncology. ? A special shoutout to our entire team for their incredible contributions. Fernanda Staquicini, Steve Alley, Vanessa de Oliveira, M.Sc., Ph.D., Sara Todd Sullivan, Kellogg Parsons, MD, MHS, FACS; Reena R Desai, Isan Chen, Mike Bartosiewicz, Dawn C., Laura F., Yongjian Wu, PhD; Kirstin Barnhart, S. Sonya Kim, Pourya Pourhosseini, PharmD, RPh, Allen Albright, PhD #WorldADCAwards #Oncology #ADCTechnology #Innovation #Teamwork

We are excited to share that?Reena R Desai?has joined MBrace as #ChiefLegalOfficer and Corporate Secretary. Reena brings almost 25 years of experience from various?#biotech and?#pharmaceutical companies.?She will be responsible for shaping the company’s?#legal strategy at MBrace. Welcome, Reena!?

It’s an exciting time in the field of #oncology and #ADC innovation. It was impactful for our team to be a part of a community of dedicated and passionate individuals at #ASCO24, and we look forward to continuing to explore MBRC-101's therapeutic potential to meaningfully impact outcomes for individuals with difficult-to-treat cancers.

We look forward to presenting a trial in progress update for the Phase 1/1b study of MBRC-101 at #ASCO24. This clinical program demonstrates our commitment to both break new ground in #ADC innovation and bridge gaps within current #cancer treatment paradigms. Learn more: https://bit.ly/4bD5Fos

The Wall Street Journal?recently featured MBrace?along with other leading innovators in the #ADC field, highlighting our SPARTA platform’s ability to search for potential novel targets that allow #ADCs to zero in on #tumors, exit the bloodstream and enter #cancer cells: https://bit.ly/3y3KkFF

We were honored to present?and?participate in #AACR24. The strength of scientific progress and incredible resolve to meaningfully advance the treatment of #cancer?has never been more apparent. We are inspired by the connections we made with fellow innovators, advocates, survivors and patients.

#ICYMI: STAT recently covered the appointment of MBrace chief scientific officer Steve Alley, Ph.D., and offered a glimpse into his?unique interests?and hobbies outside of the lab, including hiking and bird watching.?Read more?about Steve’s?favorite hiking and bird watching experiences, including a chance?encounter with a?Magellanic penguin,?here: https://lnkd.in/ei53g6J5

Our Director of Research & Development, Fernanda Staquicini, Ph.D., will be presenting at #AACR24 on Sunday, April 7. We’re excited to connect with industry peers to showcase the strides MBrace is making in the #oncology space, specifically around our investigational #ADC, MBRC-101. Learn more: https://lnkd.in/ekq5E7Pz

Please join us in welcoming the newest addition to our #leadership team, Steve Alley, Ph.D., joining as chief scientific officer! With over 20 years of experience in discovery and #drugdevelopment, from leading clinical development programs and overseeing a robust commercial portfolio of #antibodydrugconjugates, Dr. Alley will play a pivotal role in driving our #research and development efforts forward. #oncologynews #biotech #stem #oncology https://lnkd.in/e3wqf7g8

It is an honor to be recognized by?BioPharma Reporter as one of the top #ADC startups favored by venture capital #investors in 2023. Read the full article to discover how we’re making strides in the #oncology space following our our $85 million Series B financing led by TPG:?https://lnkd.in/efTvW7xV #cancer #biotech #innovation #science #stem?